Supply of product by Novartis Vaccines and Diagnostics Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, was introduced to regulate the provision of therapeutic goods, including medicines, medical devices, and blood products, to ensure their safety, quality, and efficacy. In a specific instance, the Department of Health and Ageing, through the Therapeutic Goods Administration, issued a notice on August 8, 2013, granting consent for the supply of the prepandemic (AFLUNOV) influenza vaccine H5N1, manufactured by Novartis Vaccines and Diagnostics. This consent, under sections 14 and 14A of the Act, was necessary because the product did not conform to the Therapeutic Goods Order No. 69, particularly concerning the labeling of active ingredients. The consent is subject to conditions outlined in subsection 15(1) of the Act and applies indefinitely, allowing for continued supply while ensuring compliance with regulatory standards.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration (TGA) within the Department of Health and Ageing, governs the regulation of therapeutic goods in Australia, including their manufacture, supply, and advertising. Section 14 and 14A of the Act pertain to the supply of specific therapeutic goods that do not conform to regulatory standards, such as labelling requirements. In this particular case, the delegate of the Secretary has consented to the supply of the prepandemic (AFLUNOV) influenza vaccine H5N1, which does not meet the labelling requirements stipulated in Therapeutic Goods Order (TGO) 69. This consent applies to Novartis Vaccines and Diagnostics, located in North Ryde, NSW. The consent is granted subject to certain conditions and applies indefinitely, underscoring the Act's role in ensuring that therapeutic goods available in the market meet necessary safety and quality standards. The Act's jurisdiction extends nationally, ensuring uniform standards across all states and territories.

Key Provisions

The key operative sections of the Therapeutic Goods Act 1989 (the Act) in this context are sections 14 and 14A. Section 14 permits the delegate of the Secretary to give consent for the supply of therapeutic goods that do not fully comply with the standards set out in the Therapeutic Goods Orders (TGO), while section 14A allows for the imposition of conditions to ensure the safety, quality, and efficacy of the therapeutic goods. In this instance, the delegate has granted consent (section 14) for the supply of the influenza vaccine AFLUNOV, which does not conform to paragraph 3(2)(b) of TGO 69, specifically concerning the labelling of active ingredients (section 14A). The obligations and requirements imposed by the Act on the parties involved include ensuring that therapeutic goods are supplied in a manner that does not pose an unacceptable risk to public health and safety. In this case, the Company must comply with the conditions set by the delegate to ensure the safety and efficacy of the influenza vaccine. The consent is subject to conditions that must be adhered to indefinitely, as stipulated in section 15(1) of the Act. These conditions are designed to mitigate any potential risks associated with the non-conformance of the product to the TGO. The Therapeutic Goods Act 1989 also provides for offences, penalties, and consequences for breaches of the Act or its regulations. If any party fails to comply with the conditions of consent or breaches the Act in any way, they may be subject to enforcement actions. Such actions can include fines, imprisonment, or both, depending on the severity of the breach. While the specific penalties are not detailed in this instance, the Act generally provides for significant penalties, including fines of up to $2,200,000 for corporations and $440,000 for individuals, alongside imprisonment terms that can extend to several years. These measures ensure that parties adhere to the legislative requirements designed to protect public health.